Comparative Pharmacology
Head-to-head clinical analysis: FLUXID versus PANTOPRAZOLE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUXID versus PANTOPRAZOLE SODIUM.
FLUXID vs PANTOPRAZOLE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLUXID is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin availability in the synaptic cleft.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
1-2 g IV every 8 hours; maximum 6 g/day.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
None Documented
None Documented
Terminal half-life: 12 hours (range 10–14 hours). In renal impairment (CrCl <30 mL/min), half-life prolonged to 24–36 hours; dose adjustment required.
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%.
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor